D3 Bio's D3S-001 Receives Two Major FDA Designations for Treating KRAS G12C-Mutated Cancers D3 Bio, Inc. has announced that its drug D3S-001 has received FDA Breakthrough Therapy and Orphan Drug Designations for KRAS G12C-mutated cancers, highlighting its potential.

D3 Bio's D3S-001 Receives Two Major FDA Designations for Treating KRAS G12C-Mutated Cancers #Shanghai #United_States #KRAS_G12C #D3S-001 #D3_Bio

InxMed Reveals Groundbreaking Data on Ifebemtinib and KRAS Inhibitor for Cancer Treatments InxMed Co., Ltd has unveiled promising Phase Ib/II trial results for Ifebemtinib combined with a KRAS G12C inhibitor, showcasing notable efficacy in treating various solid tumors.

InxMed Reveals Groundbreaking Data on Ifebemtinib and KRAS Inhibitor for Cancer Treatments #China #Nanjing #Cancer_Treatment #KRAS_G12C #Ifebemtinib

FDA Approves Innovative Treatment for KRAS G12C-Colorectal Cancer, Offering Hope for Patients Amgen has achieved FDA approval for LUMAKRAS combined with Vectibix to treat metastatic colorectal cancer with KRAS G12C mutation, enhancing patient outcomes significantly.

FDA Approves Innovative Treatment for KRAS G12C-Colorectal Cancer, Offering Hope for Patients #United_States #Thousand_Oaks #KRAS_G12C #Vectibix #LUMAKRAS